| Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical … C Cremolini, D Rossini, E Dell’Aquila, S Lonardi, E Conca, M Del Re, ... JAMA oncology 5 (3), 343-350, 2019 | 296 | 2019 |
| The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients M Del Re, E Biasco, S Crucitta, L Derosa, E Rofi, C Orlandini, M Miccoli, ... European urology 71 (4), 680-687, 2017 | 244 | 2017 |
| PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC M Del Re, R Marconcini, G Pasquini, E Rofi, C Vivaldi, F Bloise, ... BRITISH JOURNAL OF CANCER, 1-5, 2018 | 203 | 2018 |
| DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis S Terrazzino, S Cargnin, M Del Re, R Danesi, PL Canonico, ... Pharmacogenomics 14 (11), 1255-1272, 2013 | 153 | 2013 |
| Clinical pharmacology of intravitreal anti-VEGF drugs S Fogli, M Del Re, E Rofi, C Posarelli, M Figus, R Danesi Eye 32 (6), 1010-1020, 2018 | 146 | 2018 |
| Contribution of KRAS mutations and c. 2369C> T (p. T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA M Del Re, M Tiseo, P Bordi, A D'Incecco, A Camerini, I Petrini, M Lucchesi, ... | 91 | 2016 |
| Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy R Minari, P Bordi, M Del Re, F Facchinetti, F Mazzoni, F Barbieri, ... Lung Cancer 115, 21-27, 2018 | 88 | 2018 |
| Concise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment E Arrigoni, M Del Re, S Galimberti, G Restante, E Rofi, S Crucitta, ... Stem cells translational medicine 7 (3), 305-314, 2018 | 77 | 2018 |
| Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. M Del Re, C Vivaldi, E Rofi, E Vasile, M Miccoli, C Caparello, P d'Arienzo, ... Sci Rep. 7 (1), 7931, 2017 | 75 | 2017 |
| Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity A Di Paolo, G Bocci, M Polillo, M Del Re, T Di Desidero, M Lastella, ... Current drug metabolism 12 (10), 932-943, 2011 | 73 | 2011 |
| Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer P Bordi, M Del Re, R Danesi, M Tiseo Translational lung cancer research 4 (5), 584, 2015 | 72 | 2015 |
| Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy M Del Re, S Crucitta, G Gianfilippo, A Passaro, I Petrini, G Restante, ... International journal of molecular sciences 20 (16), 3951, 2019 | 71 | 2019 |
| Updates on liquid biopsy: Current trends and future perspectives for clinical application in solid tumors P Pinzani, V D’Argenio, M Del Re, C Pellegrini, F Cucchiara, F Salvianti, ... Clinical Chemistry and Laboratory Medicine (CCLM) 59 (7), 1181-1200, 2021 | 69 | 2021 |
| Pathophysiology and pharmacological targets of VEGF in diabetic macular edema S Fogli, S Mogavero, CG Egan, M Del Re, R Danesi Pharmacological research 103, 149-157, 2016 | 66 | 2016 |
| Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients M Del Re, I Bertolini, S Crucitta, L Fontanelli, E Rofi, C De Angelis, ... Breast Cancer Research and Treatment 178, 57-62, 2019 | 62 | 2019 |
| The role of drug-drug interactions in prostate cancer treatment: focus on abiraterone acetate/prednisone and enzalutamide M Del Re, S Fogli, L Derosa, F Massari, P De Souza, S Crucitta, ... Cancer treatment reviews 55, 71-82, 2017 | 61 | 2017 |
| The molecular profiling of solid tumors by liquid biopsy: A position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies A Russo, L Incorvaia, M Del Re, U Malapelle, E Capoluongo, V Gristina, ... ESMO open 6 (3), 100164, 2021 | 58 | 2021 |
| Detection of ALK and KRAS mutations in circulating tumor DNA of patients with advanced ALK-positive NSCLC with disease progression during crizotinib treatment P Bordi, M Tiseo, E Rofi, I Petrini, G Restante, R Danesi, M Del Re Clinical lung cancer 18 (6), 692-697, 2017 | 53 | 2017 |
| Radiomics and liquid biopsy in oncology: the holons of systems medicine E Neri, M Del Re, F Paiar, P Erba, P Cocuzza, D Regge, R Danesi Insights into Imaging 9 (6), 915-924, 2018 | 52 | 2018 |
| Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer M Santoni, F Massari, M Del Re, C Ciccarese, F Piva, G Principato, ... Expert opinion on investigational drugs 24 (6), 809-824, 2015 | 50 | 2015 |
Romano DanesiProfessor of Pharmacology, University of PisaVerified email at unipi.it
